Sarah Ko
Psychiatric/Mental Health · Los Angeles, CANPI 1336699933
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,534 of the $34,251 with a category attached, or 68.7%. Teva Pharmaceuticals USA, Inc. accounts for 81.0% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $16,120, more than ten times the $906 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 383 payments — averaging $89.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$28K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$902
- Alkermes, Inc.$722
- Otsuka America Pharmaceutical, Inc.$547
- Neurocrine Biosciences, Inc.$460
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$23,53469%
- Travel & lodging$6052%
- Food & beverage$9,70528%
- Education$4071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 150 | $27,746 |
| Johnson & Johnson | 51 | $1,517 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $902 |
| Alkermes, Inc. | 26 | $722 |
| Otsuka America Pharmaceutical, Inc. | 25 | $547 |
| Neurocrine Biosciences, Inc. | 13 | $460 |
| Lundbeck LLC | 16 | $370 |
| Indivior Inc. | 17 | $332 |
| AbbVie | 14 | $326 |
| Novo Nordisk | 3 | $266 |
| E.r. Squibb & Sons, L.L.C. | 7 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $177 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $144 |
| Tris Pharma Inc | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| Supernus Pharmaceuticals, Inc. | 4 | $78 |
| Amgen | 2 | $53 |
| Almatica Pharma LLC | 2 | $50 |
| Stryker | 1 | $31 |
| Merz North America, Inc. | 1 | $27 |
| Corium, LLC | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$24,606
- LYBALVI$419
- CAPLYTA$247
- Wegovy$241
- Austedo XR$224
- INVEGA SUSTENNA$137
- Dyanavel XR$125
- Quillichew ER$125
- Quillivant$125
- AUSTEDO$124
- Auvelity$120
- INGREZZA$116
How this compares
$34,251 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 17 | $58,530 |
| Abilify MaintenaAripiprazole | 11 | $30,275 |
| Aripiprazole | 17 | $1,675 |
| Clozapine | 23 | $1,096 |
| Haloperidol Lactate | 12 | $560 |
| Ziprasidone Hcl | 13 | $401 |
| Quetiapine Fumarate | 22 | $334 |
| Haloperidol Decanoate | 18 | $261 |
| Gabapentin | 51 | $240 |
| Clonazepam | 37 | $163 |
| Risperidone | 27 | $159 |
| Benztropine Mesylate | 27 | $156 |
| Lithium Carbonate | 12 | $129 |
| Topiramate | 12 | $90 |
| Bupropion Hcl SrBupropion Hcl | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,517 | $58,53017 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $547 | $30,27511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Los Angeles
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Prince OkosunLos Angeles$12K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.